A number of gastrointestinal complications occur in common variable immunodeficiency (CVID). Infections are one cause, but various forms of severe non-infectious enteropathy also lead to substantial morbidity. The presence of T cell lymphocytic infiltrates in the mucosa have suggested that vedolizumab, a humanized monoclonal antibody which binds to alpha4 beta7 integrin and inhibits the migration of effector T-lymphocytes into gastrointestinal tissues, would be an effective treatment. A previous report of 3 CVID cases suggested benefit in 2 subjects. In this study 7 CVID patients with severe enteropathy were treated with vedolizumab. Four of the 7 completed vedolizumab induction therapy but 3 subjects had acute decompensation during induction and treatment was stopped. While one subject showed improvement, 6 of the 7 patients were withdrawn from therapy. While vedolizumab may be of use in some CVID subjects, it was not ultimately found helpful in most of these patients.

中文翻译：

---

维多珠单抗治疗常见可变免疫缺陷相关性肠病的病例系列。

常见的可变免疫缺陷症（CVID）会引起许多胃肠道并发症。感染是一种原因，但各种形式的严重非感染性肠病也导致大量发病。粘膜中T细胞淋巴细胞浸润的存在表明，维多珠单抗是一种人源化单克隆抗体，可与alpha4 beta7整联蛋白结合并抑制效应T淋巴细胞向胃肠道组织的迁移，是一种有效的治疗方法。之前的3例CVID病例报告表明，有2例患者受益。在这项研究中，使用维多珠单抗治疗了7例严重肠病的CVID患者。7种完成的维多珠单抗诱导治疗中有4种发生，但是3名受试者在诱导期间出现急性代偿失调，并停止治疗。虽然一个主题显示出了进步，7名患者中有6名退出治疗。尽管维多珠单抗可能在某些CVID受试者中使用，但最终并未发现对大多数这些患者有帮助。